Shenzhen Glory Medical Co.,Ltd. (002551.SZ)
CNY 3.58
(-0.83%)
CNY 3.58
(-0.83%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.19 Billion CNY | -6.49% |
| 2022 | 1.27 Billion CNY | -28.74% |
| 2021 | 1.79 Billion CNY | -21.04% |
| 2020 | 2.26 Billion CNY | 48.11% |
| 2019 | 1.53 Billion CNY | -6.11% |
| 2018 | 1.63 Billion CNY | -18.74% |
| 2017 | 2 Billion CNY | 3.11% |
| 2016 | 1.94 Billion CNY | 16.79% |
| 2015 | 1.66 Billion CNY | 42.81% |
| 2014 | 1.16 Billion CNY | 59.64% |
| 2013 | 730.9 Million CNY | 73.48% |
| 2012 | 421.31 Million CNY | 20.92% |
| 2011 | 348.42 Million CNY | 29.03% |
| 2010 | 270.03 Million CNY | 29.51% |
| 2009 | 208.51 Million CNY | 51.02% |
| 2008 | 138.06 Million CNY | 18.64% |
| 2007 | 116.37 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 371.17 Million CNY | 6.09% |
| 2024 Q2 | 349.87 Million CNY | 28.79% |
| 2024 Q1 | 271.67 Million CNY | -0.88% |
| 2023 Q2 | 290.57 Million CNY | -6.08% |
| 2023 Q3 | 318.82 Million CNY | 9.72% |
| 2023 Q4 | 274.08 Million CNY | -14.03% |
| 2023 FY | 1.19 Billion CNY | -6.49% |
| 2023 Q1 | 309.4 Million CNY | -7.83% |
| 2022 Q3 | 312.39 Million CNY | 117.6% |
| 2022 Q2 | 143.56 Million CNY | -70.34% |
| 2022 Q1 | 484.05 Million CNY | -24.17% |
| 2022 Q4 | 335.69 Million CNY | 7.46% |
| 2022 FY | 1.27 Billion CNY | -28.74% |
| 2021 Q3 | 279.52 Million CNY | -13.39% |
| 2021 Q4 | 638.35 Million CNY | 128.37% |
| 2021 Q2 | 322.74 Million CNY | -41.28% |
| 2021 Q1 | 549.66 Million CNY | -23.84% |
| 2021 FY | 1.79 Billion CNY | -21.04% |
| 2020 Q4 | 721.73 Million CNY | 24.68% |
| 2020 FY | 2.26 Billion CNY | 48.11% |
| 2020 Q1 | 359.25 Million CNY | -3.5% |
| 2020 Q2 | 607.44 Million CNY | 69.08% |
| 2020 Q3 | 578.86 Million CNY | -4.71% |
| 2019 Q3 | 362.73 Million CNY | -18.07% |
| 2019 Q4 | 372.29 Million CNY | 2.63% |
| 2019 FY | 1.53 Billion CNY | -6.11% |
| 2019 Q1 | 353.07 Million CNY | 24.96% |
| 2019 Q2 | 442.72 Million CNY | 25.39% |
| 2018 Q3 | 276.08 Million CNY | -51.64% |
| 2018 Q1 | 500.94 Million CNY | 1.62% |
| 2018 FY | 1.63 Billion CNY | -18.74% |
| 2018 Q4 | 282.54 Million CNY | 2.34% |
| 2018 Q2 | 570.86 Million CNY | 13.96% |
| 2017 Q4 | 492.94 Million CNY | -0.93% |
| 2017 Q2 | 417.79 Million CNY | -30.15% |
| 2017 Q3 | 497.56 Million CNY | 19.09% |
| 2017 FY | 2 Billion CNY | 3.11% |
| 2017 Q1 | 598.16 Million CNY | 3.28% |
| 2016 Q1 | 505.76 Million CNY | -9.16% |
| 2016 Q3 | 516.45 Million CNY | 49.83% |
| 2016 Q4 | 579.13 Million CNY | 12.14% |
| 2016 FY | 1.94 Billion CNY | 16.79% |
| 2016 Q2 | 344.69 Million CNY | -31.85% |
| 2015 Q4 | 556.76 Million CNY | 129.72% |
| 2015 Q2 | 565.6 Million CNY | 87.54% |
| 2015 Q1 | 301.58 Million CNY | -11.54% |
| 2015 FY | 1.66 Billion CNY | 42.81% |
| 2015 Q3 | 242.36 Million CNY | -57.15% |
| 2014 FY | 1.16 Billion CNY | 59.64% |
| 2014 Q2 | 253.45 Million CNY | 8.34% |
| 2014 Q4 | 340.92 Million CNY | 0.73% |
| 2014 Q3 | 338.45 Million CNY | 33.54% |
| 2014 Q1 | 233.94 Million CNY | -26.21% |
| 2013 Q2 | 139 Million CNY | -7.4% |
| 2013 FY | 730.9 Million CNY | 73.48% |
| 2013 Q3 | 124.72 Million CNY | -10.27% |
| 2013 Q4 | 317.05 Million CNY | 154.2% |
| 2013 Q1 | 150.11 Million CNY | 35.33% |
| 2012 Q4 | 110.92 Million CNY | 24.65% |
| 2012 Q1 | 117.56 Million CNY | 17.47% |
| 2012 Q2 | 103.82 Million CNY | -11.69% |
| 2012 Q3 | 88.99 Million CNY | -14.29% |
| 2012 FY | 421.31 Million CNY | 20.92% |
| 2011 Q4 | 100.08 Million CNY | 94.52% |
| 2011 Q2 | 119.12 Million CNY | 53.17% |
| 2011 Q1 | 77.76 Million CNY | 12.01% |
| 2011 FY | 348.42 Million CNY | 29.03% |
| 2011 Q3 | 51.45 Million CNY | -56.81% |
| 2010 Q3 | 69.89 Million CNY | -18.81% |
| 2010 Q1 | 44.62 Million CNY | 0.0% |
| 2010 Q2 | 86.08 Million CNY | 92.93% |
| 2010 Q4 | 69.43 Million CNY | -0.67% |
| 2010 FY | 270.03 Million CNY | 29.51% |
| 2009 FY | 208.51 Million CNY | 51.02% |
| 2008 FY | 138.06 Million CNY | 18.64% |
| 2007 FY | 116.37 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 75.47 Billion CNY | 98.42% |
| Realcan Pharmaceutical Group Co., Ltd. | 8.03 Billion CNY | 85.153% |